Merriman Wealth Management’s ClearPoint Neuro CLPT Stock Holding History

Merriman Wealth Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,560	Closed	-$168K	–	189
2020 Q4	$168K	Sell	10,560 -35,440	-77%	-$318K	0.02%	197
2020 Q3	$251K	Sell	46,000 -1,690	-4%	-$7.45K	0.04%	146
2020 Q2	$170K	Sell	47,690 -49,010	-51%	-$182K	0.03%	154
2020 Q1	$346K	Sell	96,700 -4,528	-4%	-$22.2K	0.08%	108
2019 Q4	$486K	Buy	101,228 +27,496	+37%	+$114K	0.09%	127
2019 Q3	$373K	Buy	+73,732	New	+$302K	0.08%	131

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

CCM

Conway Capital Management Burbank, California $214M AUM 22.99% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Merriman Wealth Management's CLPT Position: Q1 2021 in Review

Merriman Wealth Management sold out of ClearPoint Neuro (CLPT) in Q1 2021, closing a stake of 10,560 shares — an estimated $168K sold.

Merriman Wealth Management first reported a position in CLPT in Q3 2019 and held it in 6 quarters. The position peaked at $486K in Q4 2019. 50 funds tracked by Wall St. Rank hold CLPT as of Q1 2021.

Merriman Wealth Management reported no remaining ClearPoint Neuro position as of Q1 2021 after selling out during the quarter.
Merriman Wealth Management sold 10,560 ClearPoint Neuro shares in Q1 2021, an estimated $168K.
Merriman Wealth Management first reported a position in ClearPoint Neuro in Q3 2019 and held it in 6 quarters.
Merriman Wealth Management's ClearPoint Neuro position peaked at $486K in Q4 2019.
50 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2021.

Based on Merriman Wealth Management's 13F filing for Q1 2021, filed 10 May 2021.